Overview Request Sample Pages Request Customization Download PDF
You are viewing: South Korea Cardiac Marker Testing Market analysis
Part of: Cardiac Marker Testing Market (Global)

The South Korea Cardiac Marker Testing Market was valued at $59.7 Million in 2026 and projected to reach to $103.6 Million by 2031, representing a compound annual growth rate of 11.7%. South Korea's cardiac marker testing market is poised for sustained growth through 2031, driven by an aging population with rising cardiovascular disease incidence and the country's commitment to advanced diagnostic capabilities.

South Korea Cardiac Marker Testing Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Cardiac Marker Testing Market Trends and Insights

  • This 11.7% compound annual growth rate reflects South Korea's advanced healthcare infrastructure, aging population, and increasing prevalence of cardiovascular diseases.
  • South Korea's investment in diagnostic technologies and hospital modernization initiatives are driving demand for rapid, accurate cardiac biomarker assays. The South Korea market benefits from strong regulatory frameworks, high healthcare spending, and widespread adoption of point-of-care testing solutions.
  • South Korea's emphasis on early disease detection and preventive cardiology is accelerating the uptake of troponin, BNP, and myoglobin testing across both primary and tertiary care settings.
  • South Korea's competitive pharmaceutical and diagnostics sector continues to innovate, supporting market expansion through localized product development and clinical partnerships..

Key Market Statistics

  • CAGR (2026-2031) 11.7% CAGR
  • Market Size, 2026 ~USD 59.7 Million
  • Forecast, 2031 ~USD 103.6 Million
  • Country South Korea

South Korea Cardiac Marker Testing Market Overview

Rapid Market Expansion :

South Korea's cardiac marker testing market is projected to grow from USD 59.7 million in 2026 to USD 103.6 million by 2031, representing a robust 11.7% CAGR, outpacing the global average of 10.3%.

Aging Population Dynamics :

South Korea's rapidly aging demographic is driving increased cardiovascular disease prevalence, creating sustained demand for advanced cardiac diagnostic testing and early detection solutions.

Advanced Healthcare Infrastructure :

South Korea's world-class healthcare system and significant investment in diagnostic technologies position it as a leader in cardiac marker testing adoption and innovation in the Asia-Pacific region.

Hospital Modernization Initiatives :

Ongoing investments in hospital infrastructure and laboratory automation across South Korea are accelerating the adoption of high-throughput cardiac marker testing platforms and point-of-care diagnostics.

South Korea Cardiac Marker Testing Market Dynamics

  • The 11.7% CAGR reflects strong healthcare spending, technological innovation, and increasing awareness of early cardiac disease detection among both healthcare providers and patients. Key growth catalysts include hospital modernization programs, integration of AI-powered diagnostic tools, and expanding reimbursement coverage for cardiac biomarker testing.
  • South Korea's emphasis on preventive healthcare and precision medicine will further accelerate market penetration, particularly in urban centers and tertiary care facilities, positioning the country as a significant growth market within Asia-Pacific..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
    Top Companies

      Medical Devices

      Top Technologies
        Top Companies

          Key Takeaways

          • South Korea's cardiac marker testing market is projected to grow from USD 59.7M (2026) to USD 103.6M (2031) at an 11.7% CAGR.
          • South Korea's aging demographic and rising cardiovascular disease burden are primary drivers of increased diagnostic testing demand.
          • South Korea's advanced healthcare infrastructure and high diagnostic spending support rapid adoption of innovative cardiac biomarker assays.
          • South Korea's regulatory environment and local diagnostics innovation ecosystem position the country as a key Asia-Pacific growth market.

          Cardiac Marker Testing Market Report Scope

          Report Metric Details
          Base Year 2026
          Fastest Growing Segment OTHER CARDIAC BIOMARKERS (Biomarker Type)
          Forecast Period 2026–2031
          Growth Rate CAGR of 10.3% from 2026 to 2031
          Largest Segment SINGLEPLEX ASSAY (Assay Format)
          Market Size Base Year (Billions) ~USD 5.55 (2026)
          Revenue Forecast (Billions) ~USD 9.06 (2031)
          Segments Covered Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User

          South Korea Cardiac Marker Testing Market Report Segmentation

          8 segment dimensions are covered across the global market.

          By Product

          • Instruments
          • Reagents & Kits

          By Technology

          • Clinical Chemistry
          • Immunoassay
          • Immunoassays

          By Type

          • Chemiluminescence
          • Contract Testing Laboratories
          • Elisa
          • Hospital Laboratories
          • Immunofluorescence
          • Lateral Flow Immunoassay
          • Reference Laboratories

          By Indication

          • Acute Coronary Syndrome
          • Atherosclerosis
          • Congestive Heart Failure
          • Ischemia
          • Myocardial Infarction

          By Biomarker Type

          • Brain Natriuretic Peptide
          • Creatinine Kinase-Mb
          • High-Sensitivity C-Reactive Protein
          • Homocysteine
          • Myoglobin
          • Other Cardiac Biomarkers
          • Troponin I & T

          By Point Of Testing

          • Lab Tests
          • Poc Tests

          By Assay Format

          • Multiplex Assay
          • Multiplex Assays
          • Singleplex Assay
          • Singleplex Assays

          By End User

          • Academic Institutes
          • Laboratory Testing Facilities
          • Point-Of-Care Testing

          Target Audience

          • In Vitro Diagnostics Manufacturers : IVD companies need South Korea-specific market data to develop localized product strategies, identify distribution partnerships, and capitalize on the country's 11.7% CAGR growth opportunity in cardiac testing.
          • Healthcare System Administrators : Hospital and clinic leaders require detailed market insights to optimize diagnostic service offerings, justify capital investments in cardiac testing infrastructure, and benchmark against South Korean healthcare standards.
          • Medical Device Investors : Private equity and venture capital firms need comprehensive South Korea market analysis to evaluate investment opportunities in diagnostic companies, assess market maturity, and project financial returns.
          • Clinical Laboratory Directors : Laboratory managers need South Korea-focused data to make informed decisions about test menu expansion, equipment procurement, and competitive positioning within the country's growing cardiac diagnostics market.
          • Healthcare Consultants & Advisors : Strategy consultants require South Korea-specific market intelligence to advise clients on market entry, partnership opportunities, and growth strategies in the cardiac marker testing segment.

          Key Companies in the South Korea Cardiac Marker Testing Market

          CompanyHQOwnershipStrongest segments
          ABBOTT LABORATORIESUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
          DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software),
          SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
          THERMO FISHER SCIENTIFICUnited StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
          BIO-RAD LABORATORIESUnited StatesPublic CompanyLife Science,Clinical Diagnostics,
          BIOMéRIEUX SAFrancePublic CompanyClinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA),
          BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyMedical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems),
          DIASORIN SPAItalyPublic CompanyImmunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory,
          REVVITYUnited StatesPublic CompanyDiagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software,
          TOSOH CORPORATIONJapanPublic CompanyBasic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins),
          QUIDEL CORPORATIONUnited StatesPublic CompanyLabs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care,
          GUANGZHOU WONDFO BIOTECH CO., LTD.ChinaPublic CompanyRapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform,

          ABBOTT LABORATORIES

          Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.

          DANAHER CORPORATION

          Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.

          SIEMENS HEALTHINEERS AG

          Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.

          THERMO FISHER SCIENTIFIC

          Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.

          BIO-RAD LABORATORIES

          Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.

          BIOMéRIEUX SA

          bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.

          BECTON, DICKINSON AND COMPANY

          Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.

          DIASORIN SPA

          DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.

          REVVITY

          Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.

          TOSOH CORPORATION

          Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.

          QUIDEL CORPORATION

          Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.

          GUANGZHOU WONDFO BIOTECH CO., LTD.

          Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.

          Reasons to Buy this Report

          • Market-Specific Growth Projections : Access precise forecasts for South Korea's cardiac marker testing market with detailed 2026-2031 projections, enabling accurate business planning and investment decisions tailored to this high-growth Asian market.
          • Competitive Landscape Intelligence : Understand South Korea's unique competitive dynamics, including local and international players, market consolidation trends, and strategic positioning within the country's advanced healthcare ecosystem.
          • Regulatory & Reimbursement Insights : Gain critical knowledge of South Korea's healthcare regulations, insurance coverage policies, and reimbursement frameworks specific to cardiac marker testing to optimize market entry and pricing strategies.
          • Demographic & Clinical Trends : Leverage detailed analysis of South Korea's aging population, cardiovascular disease prevalence, and clinical practice patterns to identify high-opportunity segments and customer acquisition strategies.
          • Technology Adoption Patterns : Discover South Korea-specific insights on diagnostic technology adoption rates, hospital automation trends, and point-of-care testing preferences to align product development and go-to-market strategies.

          Frequently asked questions

          What is the current size of South Korea's cardiac marker testing market?

          South Korea's cardiac marker testing market was valued at USD 59.7 million in 2026 and is expected to reach USD 103.6 million by 2031.

          What is the projected growth rate for South Korea's cardiac marker testing market?

          South Korea's cardiac marker testing market is projected to grow at a compound annual growth rate (CAGR) of 11.7% from 2026 to 2031.

          What factors are driving growth in South Korea's cardiac marker testing market?

          South Korea's market growth is driven by an aging population, rising cardiovascular disease prevalence, advanced healthcare infrastructure, high diagnostic spending, and increased adoption of point-of-care testing solutions.

          Which cardiac markers are most commonly tested in South Korea?

          South Korea's healthcare providers primarily test for troponin, B-type natriuretic peptide (BNP), and myoglobin as key cardiac biomarkers for acute coronary syndrome and heart failure diagnosis.

          How does South Korea's market compare to other Asia-Pacific countries?

          South Korea's 11.7% CAGR and advanced diagnostic infrastructure position it as one of the fastest-growing cardiac marker testing markets in the Asia-Pacific region, driven by high healthcare spending and technological adoption.

          RESEARCH METHODOLOGY

          The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.

          Secondary Research

          In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

          Primary Research

          In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

          BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS

          Cardiac Marker Testing Market Size, and Share

          Note 1: Others include sales managers, marketing managers, and product managers.
          Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

          COMPANY NAME

          DESIGNATION

          Abbott Laboratories (US)

          Sales Manager

          F. Hoffmann-La Roche AG (Switzerland)

          Product Manager

          To know about the assumptions considered for the study, download the pdf brochure

          Market Size Estimation

          Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:

          • The key players in the industry have been identified through extensive secondary research
          • The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
          • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

          The research methodology used to estimate the market size includes the following:

          Cardiac Marker Testing Market Top Down and Bottom Up Approach

          Data Triangulation

          After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

          Market Definition

          Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).

          Key Stakeholders

          • Product Manufacturers, Distributors, and Suppliers
          • Diagnostic Laboratories and Point-of-care Testing Centers
          • Research Laboratories and CROs
          • Ambulatory Testing Centers
          • Contract Testing Laboratories
          • Academic Universities and Medical Research Centers
          • Research & Development (R&D) Centers

          Report Objectives

          • To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
          • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
          • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
          • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
          • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
          • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
          • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
          • To study the impact of AI on the market, along with the macroeconomic outlook for each region

          Available customizations:

          MarketsandMarkets offers the following customizations for this market report.

          Country Information

          • Additional country-level analysis of the cardiac marker testing market

          Company profiles

          • Additional five company profiles of players operating in the cardiac marker testing market.

          Product Analysis

          • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market

           

          Get the Full Cardiac Marker Testing Market Report

          Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.

          Download Sample Pages Buy Report

          METHODOLOGY

          Need a Tailored Report?

          Customize this report to your needs

          Get 10% FREE Customization

          Customize This Report
          Fact checked
          Cite this Research
          DMCA.com Protection Status